Drug repositioning for Alzheimer's disease based on systematic 'omics' data mining

PLoS ONE

Volumn 11, Issue 12, 2016, Pages

  Zhang, Ming ^a   Schmitt Ulms, Gerold ^a   Sato, Christine ^a   Xi, Zhengrui ^a   Zhang, Yalun ^a   Zhou, Ye ^a   George Hyslop, Peter St ^a,b,c   Rogaeva, Ekaterina ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CASPASE ACTIVATED DEOXYRIBONUCLEASE; CD33 ANTIGEN; CELF1 PROTEIN; DONEPEZIL; EDROPHONIUM; EXTRACELLULAR SUPEROXIDE DISMUTASE; GALANTAMINE; MEMANTINE; PHYSOSTIGMINE; PROTEIN ABCA7; PROTEIN BIN1; PROTEIN INPP5D; PROTEIN PICALM; PROTEIN SPON1; RIVASTIGMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; COGNITION; DATA MINING; DRUG REPOSITIONING; DRUG TARGETING; EPIGENETICS; GENOMICS; HUMAN; IMMUNOMODULATION; METABOLOMICS; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PROTEOMICS; FACTUAL DATABASE; GENETICS; METABOLISM; PROCEDURES;

ALZHEIMER DISEASE; BIOMARKERS; DATA MINING; DATABASES, FACTUAL; DRUG REPOSITIONING; GENOMICS; HUMANS; METABOLOMICS; PROTEOMICS;

EID: 85007342416     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0168812     Document Type: Article

References (52)

1. Burns A, Iliffe S. Alzheimer's disease. BMJ. 2009; 338:b158. doi: 10.1136/bmj.b158 PMID: 19196745
2. Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. Cell. 2007; 131(2):215-21. doi: 10.1016/j.cell.2007.10.012 PMID: 17956719
3. Ghani M, Rogaeva E. Autosomal dominant Alzheimer's disease: underlying causes. In: Galimberti D, Scarpini E., editor. Neurodegenerative Diseases. London: Springer; 2014. p. 27-47.
4. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nature biotechnology. 2014; 32(1):40-51. doi: 10.1038/nbt.2786 PMID: 24406927
5. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's research & therapy. 2014; 6(4):37.
6. Zhang M, Luo H, Xi Z, Rogaeva E. Drug repositioning for diabetes based on 'omics' data mining. PloS one. 2015; 10(5):e0126082. doi: 10.1371/journal.pone.0126082 PMID: 25946000
7. Corbett A, Williams G, Ballard C. Drug repositioning in Alzheimer's disease. Frontiers in bioscience. 2015; 7:184-8.
8. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using geneexpression signatures to connect small molecules, genes, and disease. Science. 2006; 313 (5795):1929-35. doi: 10.1126/science.1132939 PMID: 17008526
9. Andronis C, Sharma A, Virvilis V, Deftereos S, Persidis A. Literature mining, ontologies and information visualization for drug repurposing. Briefings in bioinformatics. 2011; 12(4):357-68. doi: 10.1093/bib/ bbr005 PMID: 21712342
10. Chindelevitch L, Ziemek D, Enayetallah A, Randhawa R, Sidders B, Brockel C, et al. Causal reasoning on biological networks: interpreting transcriptional changes. Bioinformatics. 2012; 28(8):1114-21. doi: 10.1093/bioinformatics/bts090 PMID: 22355083
11. Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, Cardon LR, et al. Use of genome-wide association studies for drug repositioning. Nature biotechnology. 2012; 30(4):317-20. doi: 10.1038/nbt. 2151 PMID: 22491277
12. Wang ZY, Zhang HY. Rational drug repositioning by medical genetics. Nature biotechnology. 2013; 31 (12):1080-2. doi: 10.1038/nbt.2758 PMID: 24316641
13. Luo H, Chen J, Shi L, Mikailov M, Zhu H, Wang K, et al. DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic acids research. 2011; 39(Web Server issue):W492-8. doi: 10.1093/nar/gkr299 PMID: 21558322
14. Yang L, Wang K, Chen J, Jegga AG, Luo H, Shi L, et al. Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome-clozapine-induced agranulocytosis as a case study. PLoS computational biology. 2011; 7(3):e1002016. doi: 10.1371/journal.pcbi.1002016 PMID: 21483481
15. Yang L, Agarwal P. Systematic drug repositioning based on clinical side-effects. PloS one. 2011; 6(12): e28025. doi: 10.1371/journal.pone.0028025 PMID: 22205936
16. Wang W, Yang S, Zhang X, Li J. Drug repositioning by integrating target information through a heterogeneous network model. Bioinformatics. 2014; 30(20):2923-30. doi: 10.1093/bioinformatics/btu403 PMID: 24974205
17. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261(5123):921-3. PMID: 8346443
18. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. The New England journal of medicine. 2013; 368(2):117-27. doi: 10.1056/ NEJMoa1211851 PMID: 23150934
19. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. The New England journal of medicine. 2013; 368 (2):107-16. doi: 10.1056/NEJMoa1211103 PMID: 23150908
20. Mortimer JA, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, et al. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. International journal of epidemiology. 1991; 20 Suppl 2:S28-35.
21. Holscher C. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochemical Society transactions. 2011; 39(4):891-7. doi: 10.1042/BST0390891 PMID: 21787319
22. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. American journal of epidemiology. 2002; 156(5):445-53. PMID: 12196314
23. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research. 2003; 13 (11):2498-504. doi: 10.1101/gr.1239303 PMID: 14597658
24. Zhu F, Shi Z, Qin C, Tao L, Liu X, Xu F, et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic acids research. 2012; 40(Database issue):D1128-36. doi: 10.1093/nar/gkr797 PMID: 21948793
25. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic acids research. 2006; 34(Database issue):D668-72. doi: 10.1093/nar/gkj067 PMID: 16381955
26. Triantaphyllou E. Multi-Criteria Decision Making: A Comparative Study: Kluwer Academic Publishers 2000.
27. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid betaamyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Archives of neurology. 1999; 56(6):673-80. PMID: 10369305
28. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991; 349 (6311):704-6. doi: 10.1038/349704a0 PMID: 1671712
29. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic acids research. 2009; 37(Web Server issue):W305-11. doi: 10.1093/ nar/gkp427 PMID: 19465376
30. Huang H, Wu X, Pandey R, Li J, Zhao G, Ibrahim S, et al. C(2)Maps: a network pharmacology database with comprehensive disease-gene-drug connectivity relationships. BMC genomics. 2012; 13 Suppl 6: S17.
31. Horvath S. DNA methylation age of human tissues and cell types. Genome biology. 2013; 14(10):R115. doi: 10.1186/gb-2013-14-10-r115 PMID: 24138928
32. Zhang M, Xi Z, Ghani M, Jia P, Pal M, Werynska K, et al. Genetic and epigenetic study of ALS-discordant identical twins with double mutations in SOD1 and ARHGEF28. Journal of neurology, neurosurgery, and psychiatry. 2016.
33. Levine ME, Lu AT, Bennett DA, Horvath S. Epigenetic age of the pre-frontal cortex is associated with neuritic plaques, amyloid load, and Alzheimer's disease related cognitive functioning. Aging. 2015; 7 (12):1198-211. doi: 10.18632/aging.100864 PMID: 26684672
34. Horvath S, Ritz BR. Increased epigenetic age and granulocyte counts in the blood of Parkinson's disease patients. Aging. 2015; 7(12):1130-42. doi: 10.18632/aging.100859 PMID: 26655927
35. Lu AT, Hannon E, Levine ME, Hao K, Crimmins EM, Lunnon K, et al. Genetic variants near MLST8 and DHX57 affect the epigenetic age of the cerebellum. Nature communications. 2016; 7:10561. doi: 10. 1038/ncomms10561 PMID: 26830004
36. Butterfield DA, Pocernich CB. The glutamatergic system and Alzheimer's disease: therapeutic implications. CNS drugs. 2003; 17(9):641-52. PMID: 12828500
37. Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. Nature medicine. 2014; 20(8):886-96. doi: 10.1038/ nm.3639 PMID: 24973918
38. Liu R, Singh N, Tawa GJ, Wallqvist A, Reifman J. Exploiting large-scale drug-protein interaction information for computational drug repurposing. BMC bioinformatics. 2014; 15:210. doi: 10.1186/1471-2105-15-210 PMID: 24950817
39. Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, et al. Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood. 2005; 105(3):1256-64. doi: 10.1182/blood-2004-06-2416 PMID: 15388576
40. Lajaunias F, Dayer JM, Chizzolini C. Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. European journal of immunology. 2005; 35(1):243-51. doi: 10.1002/eji.200425273 PMID: 15597323
41. Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nature neuroscience. 2013; 16(7):848-50. doi: 10.1038/nn.3435 PMID: 23708142
42. Cowan AJ, Laszlo GS, Estey EH, Walter RB. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed). 2013; 18:1311-34.
43. Malik M, Chiles J 3rd, Xi HS, Medway C, Simpson J, Potluri S, et al. Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia. Human molecular genetics. 2015; 24(12):3557-70. doi: 10.1093/ hmg/ddv092 PMID: 25762156
44. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PloS one. 2011; 6(4):e18850. doi: 10.1371/journal.pone.0018850 PMID: 21526197
45. Bacher M, Deuster O, Aljabari B, Egensperger R, Neff F, Jessen F, et al. The role of macrophage migration inhibitory factor in Alzheimer's disease. Molecular medicine. 2010; 16(3-4):116-21. doi: 10.2119/ molmed.2009.00123 PMID: 20200619
46. Cox GM, Kithcart AP, Pitt D, Guan Z, Alexander J, Williams JL, et al. Macrophage migration inhibitory factor potentiates autoimmune-mediated neuroinflammation. Journal of immunology. 2013; 191 (3):1043-54.
47. Bryan KJ, Zhu X, Harris PL, Perry G, Castellani RJ, Smith MA, et al. Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease. Molecular neurodegeneration. 2008; 3:13. doi: 10.1186/ 1750-1326-3-13 PMID: 18786268
48. Doens D, Fernandez PL. Microglia receptors and their implications in the response to amyloid beta for Alzheimer's disease pathogenesis. Journal of neuroinflammation. 2014; 11:48. doi: 10.1186/1742-2094-11-48 PMID: 24625061
49. Kim WS, Guillemin GJ, Glaros EN, Lim CK, Garner B. Quantitation of ATP-binding cassette subfamily-A transporter gene expression in primary human brain cells. Neuroreport. 2006; 17(9):891-6. doi: 10. 1097/01.wnr.0000221833.41340.cd PMID: 16738483
50. Baruch K, Deczkowska A, Rosenzweig N, Tsitsou-Kampeli A, Sharif AM, Matcovitch-Natan O, et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease. Nature medicine. 2016; 22(2):135-7. doi: 10.1038/nm.4022 PMID: 26779813
51. Xi Z, Yunusova Y, van Blitterswijk M, Dib S, Ghani M, Moreno D, et al. Identical twins with the C9orf72 repeat expansion are discordant for ALS. Neurology. 2014; 83(16):1476-8. doi: 10.1212/WNL. 0000000000000886 PMID: 25209579
52. Zhang M, Xi Z, Zinman L, Bruni AC, Maletta RG, Curcio SA, et al. Mutation analysis of CHCHD10 in different neurodegenerative diseases. Brain: a journal of neurology. 2015; 138(Pt 9):e380.